MDxHealth SA (MDXH) Form 6-K — Oct 16, 2026
MDxHealth announced preliminary unaudited Q3 2026 revenue of approximately $22.7 million, flat versus the prior-year quarter, with tissue-based test volume down 11% to 11,232 tests. The company suspended its full-year 2026 revenue guidance of $110-115 million, stating that revenue fell short of expectations due to unexpected sales force turnover following the discontinuation of Resolve mdx. Liquid-based Exo mdx test volume more than doubled year-over-year to 11,792 from 4,600. Cash and cash equivalents stood at approximately $31.7 million as of September 30, 2026.
Key figures
- Revenue
- 22700000
- Guidance
- Full-year 2026 revenue guidance of $110-115 million suspended
- Cash Position
- 31700000
- Prior year q3 revenue
- 22700000
- Suspended guidance low
- 110000000
- Suspended guidance high
- 115000000
- Liquid test volume q3 2026
- 11792
- Tissue test volume q3 2026
- 11232
- Liquid test volume prior year
- 4600
- Tissue test volume change yoy
- -11%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.